CareDx, Inc. (NASDAQ:CDNA) Given Consensus Recommendation of "Moderate Buy" by Analysts

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $30.33.

A number of research analysts have weighed in on CDNA shares. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price target on shares of CareDx in a research report on Monday, May 5th. Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. The Goldman Sachs Group reduced their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Finally, Stephens reaffirmed an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Monday, May 5th.

Insider Transactions at CareDx

In related news, Director William A. Hagstrom sold 19,391 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $19.90, for a total value of $385,880.90. Following the sale, the director now directly owns 53,979 shares of the company's stock, valued at $1,074,182.10. This represents a 26.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Hannah Valantine sold 10,570 shares of the company's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $19.16, for a total transaction of $202,521.20. Following the transaction, the director now owns 38,994 shares of the company's stock, valued at $747,125.04. This represents a 21.33% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 129,343 shares of company stock valued at $2,238,811. Corporate insiders own 4.40% of the company's stock.

Hedge Funds Weigh In On CareDx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its holdings in CareDx by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 19,624 shares of the company's stock valued at $348,000 after acquiring an additional 640 shares during the last quarter. Sei Investments Co. lifted its holdings in CareDx by 1.7% in the 1st quarter. Sei Investments Co. now owns 47,921 shares of the company's stock valued at $851,000 after acquiring an additional 816 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in CareDx by 3.9% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company's stock valued at $425,000 after acquiring an additional 900 shares during the last quarter. Hsbc Holdings PLC lifted its stake in CareDx by 6.9% during the fourth quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock valued at $365,000 after buying an additional 1,109 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in CareDx by 1.3% during the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock valued at $1,922,000 after buying an additional 1,118 shares in the last quarter.

CareDx Price Performance

Shares of NASDAQ CDNA opened at $19.23 on Monday. The company has a market cap of $1.07 billion, a PE ratio of 16.72 and a beta of 2.18. CareDx has a 12 month low of $14.09 and a 12 month high of $34.84. The company has a 50-day simple moving average of $17.65 and a 200-day simple moving average of $19.82.

CareDx (NASDAQ:CDNA - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The firm had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same period in the previous year, the firm earned ($0.03) earnings per share. CareDx's revenue was up 17.6% compared to the same quarter last year. On average, analysts anticipate that CareDx will post -0.9 EPS for the current year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.